Lupin Posts Record Quarter with Revenue Surpassing ₹8,000 Crore, Eyes U.S. Headwinds
The Indian pharmaceutical giant reported its 16th consecutive quarter of growth, though management anticipates moderation as key U.S. generics face increased competition.
Record Performance Marks 16th Consecutive Growth Quarter
Lupin Limited reported a landmark first quarter for fiscal year 2027, with total revenues from operations exceeding ₹8,000 crore for the first time in company history. The pharmaceutical manufacturer posted revenues of ₹8,277 crore, representing 32% year-over-year growth, while EBITDA surpassed ₹2,400 crore at ₹2,464 crore, a 50% increase (earnings call, 2026-08-07).
The results mark the company's 16th consecutive quarter of year-over-year growth. CEO Vinita Gupta emphasized the breadth of the performance, noting that "ex U.S. organic revenue growth for the company has been a strong 20% plus year-over-year" with double-digit expansion across India, other developed markets, and emerging markets (earnings call, 2026-08-07).
EBITDA margins reached 30% in the quarter, up 340 basis points from 26.6% in the prior-year period, driven by improved product mix, higher India profitability, and operational efficiencies. Gross margins expanded to 74.6% from 71.3% year-over-year (earnings call, 2026-08-07).
U.S. Business Faces Competitive Pressures
While the U.S. business delivered robust growth of 43% year-over-year to $366 million, management signaled challenges ahead. The company benefited from higher volumes in its base portfolio and growth in products like tolvaptan, offset by increased competition in mirabegron (earnings call, 2026-08-07).
For the full year, Lupin expects U.S. business to reach $1.1 billion to $1.2 billion, with "additional competition in products like mirabegron and tolvaptan during the year" (earnings call, 2026-08-07). However, the company anticipates a return to growth trajectory from fiscal year 2028, supported by plans to launch over 50 products in the next three years, including "10 exclusive first to files, 5 biosimilars as well as 2 to 3 [505(b)(2)s]" (earnings call, 2026-08-07).
India and International Markets Drive Diversification
Lupin's India business grew 13.9% year-over-year to ₹2,380 crore, with core prescription business expanding 15.1% and outpacing the Indian pharmaceutical market at 1.1x IPM growth (earnings call, 2026-08-07). The diabetes segment proved particularly strong with 31.8% growth, marking a second consecutive quarter of over 20% expansion, led by market leadership in human insulin and successful launch of semaglutide injection (earnings call, 2026-08-07).
Other developed markets—Europe, Canada, and Australia—recorded 48% growth to ₹1,149 crore, now accounting for 14% of total sales versus 11% in the prior fiscal year. European sales surged 83% year-over-year (earnings call, 2026-08-07).
Emerging markets delivered 52% growth to ₹990 crore, with Brazil maintaining "strong momentum," growing 117% year-over-year in local currency driven by dapagliflozin commercialization (earnings call, 2026-08-07).
Outlook and Strategic Priorities
Management reiterated full-year guidance for "high single-digit revenue growth" with EBITDA margins around 25%, down from the 30% achieved in Q1 (earnings call, 2026-08-07). CFO Ramesh Swaminathan noted the company expects R&D spending at approximately 8% of sales for the full year, with continued focus on complex generics, respiratory products, and biosimilars (earnings call, 2026-08-07).
The company received Establishment Inspection Reports (EIRs) for its Ankleshwar and Somerset facilities with Voluntary Action Indicated (VAI) status from the U.S. FDA during the quarter (earnings call, 2026-08-07).
This article was generated by MarginX from the earnings call on 2026-08-07. It is not investment advice.